NeuroBo Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

MetaVia

14/08/2024 15:14

* NeuroBo Pharmaceuticals Inc  NRBO.OQ  reported a quarterly
adjusted loss of $1.85​​ per share for the quarter ended in
June, lower than the same quarter last year, when the company
reported EPS of -16 cents.  The mean expectation of
three analysts for the quarter was for a loss of $1.12 per
share. Wall Street expected results to range from $-1.46 to -53
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NeuroBo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.85​.
    * The company reported a quarterly loss of $10.05 million.
    * NeuroBo Pharmaceuticals Inc shares had fallen by 21.9%
this
quarter and gained 2.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 24.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for NeuroBo
Pharmaceuticals Inc is $25.00 
This summary was machine generated from LSEG data August 14 at
02:13 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.12          -1.85          Missed
 Mar. 31 2024      -3.63          -1.32          Beat
 Dec. 31 2023      -0.78          -2.28          Missed
 Sep. 30 2023      -0.86          -0.72          Beat